Shortage of Fluoxetine (Medreich) 10 mg capsule
1 Feb 2024
Policy
Fluoxetine (Medreich ®) for the treatment of major depressive disorders and obsessive-compulsive disorder is now listed on the Pharmaceutical Benefits Scheme (PBS) for the current supply shortage under Section 19A.
For more information on Fluoxetine (Medreich ®), please contact the PBS directly.
More news & views
03 May 2024
Update from Prof Bruce Singh, Chair, Mood Disorders Psychodynamic Psychotherapy Evidence Review Steering Group
Professor Bruce Singh AM, Chair, welcomes the opportunity to provide an update on the work of the Mo...
23 April 2024
Potential risk to children of fathers treated with valproate
Sanofi has issued new information regarding risk of neurodevelopmental disorders after paternal expo...
22 April 2024
Zero tolerance policy on proven sexual boundary violations
After review, the College has retained its zero tolerance policy with amendments to provide clarific...